SPOTLIGHT: Genzyme touts Synvisc data

Genzyme is touting new data from a 253-patient study that shows clear benefits from a single dose of its Synvisc osteoarthritis drug compared to a placebo. Synvisc is currently approved to be given in three doses over three weeks. The new data supports Genzyme's contention that a single dose can improve symptoms. Genzyme is disputing a decision by CMS to reimburse Synvisc at an equal rate with all viscosupplementation therapies. Report

Suggested Articles

Merck’s TIGIT-blocking prospect and PD-1 med Keytruda shrank tumors in 29% of lung cancer patients who had never tried a checkpoint inhibitor.

Merck's HIF-2α inhibitor, picked up in its $1 billion Peloton buyout, shrank kidney tumors in 36% of patients and showed promise in other tumors, too.

Amunix reported that a single dose of its lead T-cell engager caused caused large HER2-positive tumors to shrink in mice.